The Journal of Immunology, Vol 145, Issue 10 3240-3246, Copyright © 1990 by American Association of Immunologists

ARTICLES

Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region

T Masuda, S Matsushita, MJ Kuroda, M Kannagi, K Takatsuki and S Harada
Department of Biodefence and Medical Virology, Kumamoto University Medical School, Japan.

Antigenic mutants of HIV-1 were isolated from three plaque-cloned viruses by the resistance of the virus to neutralizing mAb 0.5 beta against V3 domain of viral gp120, when the viruses were passaged in the presence of the antibody. However, when chronically infected MOLT-4 cells were treated with 0.5 beta mAb, recovered viruses from the 0.5 beta-treated cells showed no antigenic changes. The extent of genomic variation among antigenically distinct isolates was examined by nucleotide sequencing, which revealed a few base substitutions in 0.5 beta-binding site of all mutants isolated. The predicted amino acid replacements within 0.5 beta reacting epitope (V3 domain) causing the altered antigenicity were also identified for each of three isolates. Particularly, in one of the mutants, the most conserved Gly-Pro-Gly-Arg region located at the center of the V3 domain was changed to Gly-Gln- Gly-Arg. The radioimmunoprecipitation and synthetic peptide analyses revealed that this Pro320----Gln substitution reduced the binding affinity with 0.5 beta, although other mutations observed in the other mutants did not affect the binding affinity in radioimmunoprecipitation. We also observed that nucleic acid substitutions in the V3 domain occurred frequently in the absence of 0.5 beta mAb during our in vitro acute infection system using MT-4 cells.

This article has been cited by other articles:

				J. Shibata, K. Yoshimura, A. Honda, A. Koito, T. Murakami, and S. Matsushita Impact of V2 Mutations on Escape from a Potent Neutralizing Anti-V3 Monoclonal Antibody during In Vitro Selection of a Primary Human Immunodeficiency Virus Type 1 Isolate J. Virol., April 15, 2007; 81(8): 3757 - 3768. [Abstract] [Full Text] [PDF]

				H. Nishitsuji, M. Kohara, M. Kannagi, and T. Masuda Effective Suppression of Human Immunodeficiency Virus Type 1 through a Combination of Short- or Long-Hairpin RNAs Targeting Essential Sequences for Retroviral Integration. J. Virol., August 1, 2006; 80(15): 7658 - 7666. [Abstract] [Full Text] [PDF]

				B. Etemad-Moghadam, Y. Sun, E. K. Nicholson, G. B. Karlsson, D. Schenten, and J. Sodroski Determinants of Neutralization Resistance in the Envelope Glycoproteins of a Simian-Human Immunodeficiency Virus Passaged In Vivo J. Virol., October 1, 1999; 73(10): 8873 - 8879. [Abstract] [Full Text] [PDF]

				C. Cheng-Mayer, A. Brown, J. Harouse, P. A. Luciw, and A. J. Mayer Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant In Vivo by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein That Modify N-Linked Glycosylation J. Virol., July 1, 1999; 73(7): 5294 - 5300. [Abstract] [Full Text]

				P. W. H. I. Parren, M. Wang, A. Trkola, J. M. Binley, M. Purtscher, H. Katinger, J. P. Moore, and D. R. Burton Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1 J. Virol., December 1, 1998; 72(12): 10270 - 10274. [Abstract] [Full Text] [PDF]

				C Callebaut, B Krust, E Jacotot, and A. Hovanessian T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells Science, December 24, 1993; 262(5142): 2045 - 2050. [Abstract] [PDF]